BRAINFOREST CAFÉ
Can Ketamine Lift Depression in Hours?
Dr. Ranji Varghese is a Mayo Clinic trained psychiatrist and sleep physician, chief medical officer of the Institute for Integrative Therapies in Minnesota, and associate professor at the University of Minnesota. He is an investigator on several psychedelic clinical trials, including studies of psilocybin and DMT and the first psychedelic research study conducted in Minnesota, and is trained in ketamine assisted and MDMA assisted therapy. He has spent more than twenty years treating people conventional psychiatry has struggled to help, from treatment resistant depression to the anxiety that follows a cancer diagnosis. He served on Minnesota’s governor’s task force on psychedelics and sits on the board of the McKenna Academy.
Dr. Ranji Varghese is a Mayo Clinic trained psychiatrist and sleep physician, chief medical officer of the Institute for Integrative Therapies in Minnesota, and associate professor at the University of Minnesota. He is an investigator on several psychedelic clinical trials, including studies of psilocybin and DMT and the first psychedelic research study conducted in Minnesota, and is trained in ketamine assisted and MDMA assisted therapy. He has spent more than twenty years treating people conventional psychiatry has struggled to help, from treatment resistant depression to the anxiety that follows a cancer diagnosis. He served on Minnesota’s governor’s task force on psychedelics and sits on the board of the McKenna Academy.
Transcript
A conversation with Ranji Varghese
Watch this Episode on YouTube
[00:00:15] Dennis McKenna: Today I’m sitting down with Dr. Ranji Varghese, a Mayo Clinic trained psychiatrist and sleep doctor, chief medical officer of the Institute for Integrative Therapies, and associate professor at the University of Minnesota.
Ranji is an investigator of several psychedelic clinical trials in Minnesota, including trials of psilocybin and dmt, among them the first psychedelic research study ever conducted in Minnesota. Rangi is one of a small group of physicians in the country working on the leading edge of psychedelic medicine.
He’s trained in ketamine assisted therapy and MDMA assisted therapy, and he spent his career treating people that conventional psychiatry has struggled to help, from treatment resistant depression to the anxiety that comes with a cancer diagnosis.
But what makes Ranji different isn’t just the science. It’s the conviction that medication only dials down symptoms. Real healing means getting to the core of a person’s suffering with compassion, safety, and with trusted support along their journey.
The medicine, as he puts it, is just the catalyst.
In this episode, we’re talking about ketamine, what it is, how it’s being used to treat depression, anxiety and other mental health conditions, and why pairing it with psychotherapy may be the key to lasting change.
He’ll break down what the research really shows and what it could mean for you or someone you love who’s still waiting for something that works. And on a personal note, I’d just like to say that I have known Ranji for years.
He treated me originally for my sleep apnea. That’s how I got to know him.
And then I realized he is so much more than just a sleep doctor, which is considerable in itself.
He’s joined the McKenna Academy as a board member a few years ago, and he and I have become close friends. And in my interactions with Reggie, even before I knew of his interest in psychedelics, I realized that Ranji exemplifies the kind of physician that you want to be treated by. He is compassionate, he understands patients distress from their own perspective, and he is just an incredible human being as well as a wonderful physician. Ranji, it’s my pleasure to invite you to the Brainforest Café.
[00:03:08] Ranji Varghese: Thank you, Dennis. That was touching.
[00:03:12] Dennis McKenna: Wonderful to see you and thank you for making this possible. This is going to be a very interesting conversation, I think, and I don’t know how it couldn’t be, because you have so much knowledge and your perspective is really valuable to our listeners. You understand both the efficacy of these kinds of therapies, the promise that they have, but you’re also well acquainted with the Pitfalls and some of the things that have to be dealt with as we as medicine attempts to integrate compounds like ketamine and other psychedelics into clinical protocols. They are not always a comfortable fit, but psychedelics are here to stay, and we have to find ways to use them effectively.
Ranji is at the cutting edge of this effort. So thank you, Ranji. I’m so honored to have you here.
What are your thoughts? Where do we talk? Where do we start?
[00:04:21] Ranji Varghese: Well, Dennis, Yeah, absolutely. I think what you said a little bit earlier is a really poignant way to start, is that I’ve been a psychiatrist for more than 20 years. I’m a sleep physician and a psychiatrist for more than 20 years.
I’ve been working with traditional and conventional therapies in psychiatry, including oral antidepressant medications, somatic therapies, ect, psychotherapy.
And throughout my years, I just have found that there’s sort of a ceiling that, you know, people will hit in terms of exploring their own psyche and getting to the core of their suffering.
And it’s not necessarily their own fault. It’s sort of a, you know, fault of the medication. We just can’t get to where we need to be.
And so there’s been this distress with me, and I would say to a lot of mental health practitioners and psychiatrists that we just needed new tools.
And, you know, I read Roland Griffith’s publication from Hopkins on occasioning mystical experiences with psilocybin, and it blew my mind because, as most psychiatrists, at least in my training, would say, there is really very little, you know, information and lectures on psychedelics, not because the training wasn’t good. I had wonderful teachers. It’s just because psychedelics were never studied beyond 1973. We, as, you know, psychedelics have been around for millennia in indigenous cultures in the Amazon, Soma and India, you name it, ibogaine in Africa, but. And then Albert Hoffman synthesized LSD and was giving LSD to psychiatrists around the world to determine its efficacy. But all of that research, all of that work sort of just dialed down in the 70s, and we lost about 50, 60 years of neuroscientific research on these. The potential for these molecules.
So really, I didn’t know much, but when I started to dig a little bit further, I thought, wow, this may be a signal to the noise. And there was just. We just saw this avalanche of information coming out on the potential for not only just psilocybin, but these other psilocybin or 5ht or serotonin 2a receptor analogs.
And, you know, I see these types of molecules as an addition to our toolkit. I never see psychedelics as sort of a panacea to anything that really sort of builds on this idea of set setting and then support the integration that comes with it.
And we’ll talk a little bit about that with ketamine. So psychedelics to me was an opportunity to go beyond what we already knew. More than that, psychedelics offer an opportunity for people to delve deeper into their mind, to be able to see reality or narratives that have been constructed as they grew from childhood to adolescence to teenage years.
And those narratives sticking, even though those narratives may not have been as may not be, may have been useful for them. And what I learned with psychedelics is they sort of melt or at least allow you to reappraise these narratives and perhaps create new narratives, which is significantly different than what traditional antidepressants were able to do.
So I said, wow, this is, this is something to study. And we studied this and we did our first, the first psychedelic trial in Minnesota in 2019.
This will probably, I hope, go on my epitaph as being the first person in Minnesota to write a prescription for psilocybin for our research patient.
And since then we’ve run clinical trials at our clinic, the Institute for Integrative Therapies.
So, as you know, Dennis, traditional classical psychedelics like LSD, dimethyltryptamine, analogs of LSD. LSD are Schedule 1 drugs by the DEA, so you cannot prescribe it to anyone. Of course, there’s a whole underground where this is used, you know, in, you know, structured settings, in sort of supportive settings, and people are getting support by them. But there are situations where it may not be supported. And so we don’t have the opportunity to do this in clinical practice. But what we can do, and one of the reasons why I was able to sort of join my partner at IIT in 2022 was to see how ketamine can be used to not only occasion sort of non ordinary states of consciousness, but as I started to read the literature on ketamine itself, I found, wow, this is a medicine that’s been around since 1962, by the way. It’s a dissociative anesthetic. It’s on the World Health Organization’s most important, one of most important medications as an anesthetic.
It’s been around for a long time and we just have never really studied it as an antidepressant, not for any other good reason except for the fact that we just used it in emergency situations. In the Vietnam War, soldiers were given ketamine to give to other soldiers in the field because it was safe to use. You didn’t need oxygen, you didn’t need ventilators. You’re able to give a soldier in the field ketamine to reduce their pain, their suffering, and also dissociate their mind from the trauma that they were experiencing in the field.
And so emergency room doctors routinely would give children ketamine if, let’s say, they broke their hand and they needed to set the bone. But children, you know, are in distress, give ketamine, children dissociate. Their thoughts are not sort of connecting with the trauma that they’re experiencing, nor they’re connecting that pain that is that they’re experiencing.
And that’s how it had been used.
But I think in the 1990s, we started to start listening to what patients said about what ketamine was being used for.
In anesthetic doses, people are out. They have no idea what’s going on. But within sub anesthetic doses, which is what we’re doing in ketamine clinics, sub anesthetic doses, people come back and say, I’m feeling better, I’m feeling more alive, I’m feeling more joy, I’m feeling less suicidal.
And in 2000, Berman and Crystal from Yale, it was the first controlled study that showed that a single infusion of racemic ketamine could rapidly reduce depression in people that were treatment resistant depression. What I mean by treatment resistant depression is that these individuals had failed at least two oral antidepressant medications and they continued to have depression. But with one infusion of ketamine, these individuals had a significant reduction in their depression scores.
And I think the most. The biggest two highlights for me that came out of that study was one, there was this reduction in suicidal ideation.
And number two, there was a rebound in the sense of joy.
There’s a depression signal called anhedonia, the inability to feel joy.
And people with depression will experience this. They’ll say, colors don’t seem bright. I taste food, doesn’t taste good. I just can’t feel the joy.
[00:12:35] Dennis McKenna: Can’t experience pleasure.
[00:12:37] Ranji Varghese: Yeah, exactly, that. That it can’t experience pleasure. And ketamine with this one infusion sort of significantly reduces. Now, on top of that, ketamine did this within a few short hours, lasting to 48 hours and even up to a week with a single infusion.
Significantly different from what oral antidepressants can do. As you know, Dennis, oral antidepressants like the SSRIs or the SNRIs are what we typically use for people that have depression. In conjunction with psychotherapy.
They take about two weeks for people to notice even something, four to six to sometimes eight weeks at a therapeutic dose, for people to sort of feel the benefits of their depression. All the while they may be struggling with their depressive features.
[00:13:36] Dennis McKenna: Right.
[00:13:37] Ranji Varghese: And that is a sea change in how we can treat depression. So imagine a patient comes into our clinic. We are carefully identifying what are their symptoms, how are they doing, what are their social structures, are they on a current antidepressant, what is their medical framework, are they psychologically stable to undergo something like ketamine. And imagine giving an infusion for a week or two or three, one, two, three weeks, let’s say, and lifting them out of their depression until their antidepressant kicks in.
So really, ketamine is a cheap molecule. It’s a generic molecule, it’s a safe molecule. And under the right structured setting, which is how we do it in our clinic, we pair it with a careful selection.
We identify what the patient’s mindset is. We carefully, you know, this is where this overlap is with traditional ceremonial psychedelics, create a comfortable setting for individuals, our clinic. And I hope that most clinics sort of adopt this sort of nature.
From the moment a patient calls in, there’s this sense that we are there to support them every step along the way. And a lot of that is because one, of course we care deeply about that, we’re intentional about that. But we know how important it is for patients and people to feel safe along that journey, physically and spiritually safe. The container itself, the clinic doesn’t look like a clinic. There’s beautiful plants, plants, there’s a lounge and a recliner, beautifully curated music, and of course, eye shades. When people have their intentions, I want to.
[00:15:24] Dennis McKenna: Yes, this is all exactly what I’d hope you were going to discuss.
I was struck by one of the first sentences in this extensive set of program notes that you furnished me. So in the first paragraph, it says we spent 40 years using ketamine to turn consciousness off.
Then the antidepressant effect requires it to be on. So you recognized the opportunities in these.
From the point of view of an anesthetic, an ineffective dose, but an interesting thing happens at that sub threshold level of anesthesia. That’s where the healing can happen.
And another thing that you discussed just now is you recognized immediately the importance of set and setting and this, this kind of context you create for patient support and you were familiar with the. I mean, this is what’s emphasized in indigenous practices with things like ayahuasca and mushrooms and indigenous practices.
Set and setting is the important determinant, almost more important than the medicine itself.
But you’re working in a clinical context where you can’t necessarily bring an ayahuascaro in to sing Icaros and so on. But you’re borrowing from this wisdom and you’re integrating it to the degree that you can. Because what I’ve seen in reviewing these notes is, and I’m completely in accord with what you say, it’s not so long the emphasis has been on the medicine.
And we give the medicine.
All the focus is on the medicine. We expect the medicine to do the work.
And the point that you make here is the medicine only creates the opportunity for the healing to take place without the support.
It may be effective temporarily, but the effect won’t last. And so that effectively working with the compounds like ketamine and other psychedelics forces the clinicians to recognize the importance of set and setting. And if that includes ritual and music and appeals to spiritual traditions and so on, there’s nothing wrong with that. You know, I mean, some criticism that I have made of medicine and many people have made, is that it’s been preoccupied with exorcising spirit out of medicine for 150 years.
Psychedelics come along and they have all these properties that basically address the spiritual side of our nature.
And maybe it’s time to let spirituality back into medicine to rediscover spirit, the spirit and medicine. And that’s what you’re doing in your practice. That’s what a lot of therapists are understanding. The tricky part is to bridge these traditional practices with the modern therapeutic protocols without sacrificing scientific rigor or standards or safety.
[00:19:03] Ranji Varghese: Absolutely, yeah. 100%, Dennis. The molecule is not the treatment.
[00:19:10] Dennis McKenna: Exactly.
[00:19:11] Ranji Varghese: Window of opportunity that the molecule can create catalyzes the opportunity to explore the mind in that safe and therapeutic space. Whatever comes up with non judgmental curiosity.
And on top of that, as you sort of mentioned, that is only as good as what you do after the medicine has sort of metabolized.
[00:19:41] Dennis McKenna: Right.
[00:19:42] Ranji Varghese: And so this is where the integration component really comes in. Because ketamine, very similar to the classical psychedelics, has.
Well, not only does it have this rapid antidepressant effect and we can go through some of the mechanisms of it, but it has the opportunity to. And it’s been shown to create new synapses.
So the dendrites on neurons in our brain, primarily the pyramidal neurons in our prefrontal cortex, and to some degree the hippocampus, these neurons that have these spines that grow out of them, are what we call dendrites. And then those dendrites we have these little tiny buds called spines, almost like buds on a branch. Dennis, if you can understand that metaphor. Of course, these buds or synapses sort of touch other dendrites and synapses. And this is what creates that communication between different neurons during periods of depression, which is somewhat to some degree an inflammatory response. Depression, depression and stress is a stress response. And immune mediators or inflammatory mediators of depression shrink these synapses and dissolve the connections between these neurons, essentially losing functional connectivity between different brain networks. With ketamine as well as classical psychedelics, you’re not. What we tend to see is that this pruning that occurred with the depression that in its inflammatory state tends to regrow the ketamine or the molecule in these classical psychedelics by way of a molecule called brain derived neurotrophic growth factor. Sort of a fertilizer for the brain, if you will, sort of seeds the molecules to regrow these synapses. You know, in fact synapses that were stressed and dwindled or had shrunk due to stress. So essentially, if you look at the arc of this story, you’re taking in this molecule, hopefully in a setting that is conducive to your own personal growth and feeling supported. The molecule, in the case of ketamine, results in this flood of a neurotransmitter, an excitatory neurotransmitter called glutamate. There’s this surge of glutamate that occurs in these brain regions, particularly in the cortex.
This glutamate surge binds to very important receptors called ampa receptors or ampa receptors.
That sort of excitation of the ampa receptors results in a downward cascade of this brain derived neurotrophic growth factors, which then results in the more that the changing of these neurons to have increased buds, if you will, to allow those buds to communicate with the rest of the brain. So you’re going from a molecule to whole brain changes in brain anatomy, which I think is a beautiful, beautiful thing. Now, even though you’ve sort of structurally sort of reconnected areas of the brain that were either over hyperactive, if you will, and you’re sort of leveling off and creating this harmony or synchrony, what do you do with that?
What do you do with that? And so this is where integration comes in. So we encourage our patients to work with our integration therapists to perhaps meet the following day. Or we will provide. The doctors will provide our own recommendations on what you want to do, what do you want to achieve? Where do you find your depression? If the answer is, I’ll give you examples, I don’t think I’m eating healthy, and that makes me unhappy. We encourage them to start engaging in behavioral programs for their diet or if they’re not sleeping enough, I’m a sleep physician. Sleep is a medicine.
Having enough sleep is an absolute medicine for your brain. If it’s about reconnecting with people that they’ve lost touch with, we encourage them to reconnect with those people or at least have the opportunity to decide on whether they want to reconnect with people. So social reconnection, we know, is very helpful for depression.
[00:24:13] Dennis McKenna: So the integration and continued support is what makes it effective. All the medicine does is it changes these things on the neurological level. You get increased density of dendrites, you get all this stuff going on, effectively a rewiring or rearrangement of the neural architecture. And you can do that. But if you don’t have the effective follow up, in other words, as you put it in your notes, the medicine creates the opportunity for the therapy. It is not the therapy.
And there are many situations where you can give ketamine, but if there’s not, you know, if you send the patient home and it’s like you’re fixed.
Which has kind of been the approach with SSRIs, you know, give the medicine and everything will be fine. And the whole field of neuroscience was deluded for years that depression had.
Was all about a chemical imbalance. And the serotonin reuptake inhibitors corrected that balance and fixed everything. And then the data emerged later. You referred to a major study, which I can’t cite by name at the moment, but a study that showed that changes in serotonin don’t have all that much to do with the effects of the SSRIs. And you, you know, this sort of whole model was, you know, I mean, important economic decisions were made in the development of these SSRIs. And they didn’t really do what we said they did.
And serotonin levels didn’t have all that much to do with depression.
So that’s kind of interesting that, you know, the sort of identified therapeutic target of these SSRIs was a red herring in some ways. What it does is it leads to these.
This neuroplastic state in which these changes can happen. Is that more or less correct?
[00:26:25] Ranji Varghese: Absolutely. I mean, the study you’re referring TO is a 2022 study by Moncrief.
Moncrief, exactly. And essentially, and I want to make this point really clear here, antidepressants, SSRIs, SNRIs, are absolutely life saving. They are super helpful for the people that need it. So there’s no reason. Why should many people. Yeah, absolutely. For many people, there’s no reason to get off your antidepressant medications, talk to your doctors about these sort of things. But what they do and antidepressants do over time. This is the thing. If I gave an individual an SSRI and I looked at their serotonin levels, you know, a few hours later, those serotonin levels would be at normal.
And so why does it take two to four to six weeks for a response for the antidepressants? I think it’s that neuroplasticity that we are starting to. It is to some degree neuroplastic. Changes in these brains connect brain networks that take a while versus a faster reboot, if you will, with ketamine and the classical psychedelics.
But what we started to use SSRIs were, is to sort of reduce the misery of suffering, which is really what they’re useful for, but without pairing that with psychotherapy and engagement in behaviors to get to the root of where they’re depressed. You know, you don’t need to have a why to be depressed, by the way. There doesn’t have to be a reason for someone to be depressed. They may be genetically sort of wired to have that right.
But you significantly increase the chances for real healing by allowing this neuroplasticity to create new ways of being. If, if you can imagine, a good example that I like to give my patients is if a child was injured psychologically early on by authority figures or bullies or a loss, a deep loss, that child who doesn’t have a lot of years of sort of contextual information of what the world really can look like, they will have sort of fixed picture of what the world look like, may look like. They may freeze in time developmentally to some degree and see the world in a different lens.
And then if their world view is look, you know, seen through that lens, that will continue to perpetuate which then the child may, you know, rely on defensive behaviors or, or defenses that at the time, in order to survive, was useful. But as an adult, those defensive posturings or maladaptive traits no longer serve them. And are probably harmful in these neuroplastic states. With sort of an awareness of maybe a reappraisal of behaviors, a reappraisal of perhaps past experiences, they may engage in behaviors that create new network patterns. And that’s the goal. And you can do that not only with the medicine, but with ongoing engagement with yourself and being honest with yourself and what you want to get out of it. And then.
And can be sort of facilitated by a therapist. SSRIs.
[00:29:50] Dennis McKenna: Yeah, go ahead, please, go ahead.
[00:29:53] Ranji Varghese: Well, what I was going to say was SSRI is what we did was we put someone on SSRI and we said, we’ll see you back in eight weeks. Eight weeks later, Doc, I’m feeling so much better. The problem didn’t go away. It was just the misery got better. And we just sort of learned to live with sort of the misery that, you know, continues. But the thought patterns perhaps never really changed. So you stop the antidepressant, those, you know, the depression could reappear.
[00:30:21] Dennis McKenna: So the medicines, all of these things, even the SSRIs, effectively effectuate these neuroplastic changes, all of which are therapeutic. Maybe a rebalancing and maybe an overcoming of this neurological rigidity that develops through the trauma and, and so forth.
But without the follow up, you can give somebody ketamine and send them home, and they will not benefit. Somewhere in your notes you said, we sent the medicine. We forgot to send the container in the envelope to these mail end things. And the container is the therapeutic container. You can’t give these things in the absence of some therapeutic container. Whether that’s a traditional context, like with ayahuasca. I often tell people ayahuasca is a liquid. Ayahuasca will fill whatever vessel you create for it. But you need to have a vessel, right? I mean, you don’t pour it out on the floor, you know, and. And that sort of applies here.
This also goes to a question we’ve talked with other people about, and I’m sure you’ve thought about it a lot. This new generation of psychedelics that are not really psychedelics and they’re neuroplastogens, I think is the word.
And again, I think you make the very strong point that the experience is indispensable. In other words, the molecules facilitate the experience. In the absence of that, it won’t be effective. So there will never be a neuroplastogen, will never do it. This is the hope that they can disassociate the drug from the therapeutic effect.
[00:32:27] Ranji Varghese: Yeah, absolutely.
We’ll find out. I mean, there are some brilliant people. Olson at UC Davis and others are working on psychoplastogens. I guess that’s the nerve for them, is to basically take the psychedelics out of the psychedelic, but still create that antidepressant response that we see with psychedelics and the neuroplastic effects that classical psychedelics do.
I’m a little skeptical about that and partly because there’s a study by Lee et al that gave ketamine at subanaesthetic doses to patients that had general anesthesia. And what they found was there was no response in their depression scores or even the neuroplastic effects. There’s something about the, I think the dissociation, the ability to sort of step out of yourself from the rigid world mental model that we make and see things in a different way and experience them somatically as well as sort of psychically to help facilitate that process. I would be happy, I would be very happy if we did come out with something that created a sort of a similar psychedelic response in terms of antidepressants as well as sort of neuroplastic or plastic effects. Because there’s a whole, you know, Dennis, I mean, in the psychedelic world, there are people that are okay with non ordinary states of consciousness, and then there are people that are deathly afraid of being able to sort of let go and be in that space. And I get that part of what we do in our clinic is to support people through that, to sort of educate them through that, to sort of, you know, make sure that they feel safe through that. But some people will not do that because they don’t want that. So if there is something that’s developed that can do that, okay, let’s do that. And there are others who will say, I want to do this in a clinical setting because I want a doctor to look at my blood pressure. I want them to make sure they look. They look at my medical history.
I want integration afterwards. And then there are people that can readily get it in, you know, in non clinical settings and still get benefit from it.
When I was.
[00:34:46] Dennis McKenna: People that are terrified of these altered states.
There’s, you know, and so they don’t want to do it. They’re so rigidified that they’re terrified of it.
So they, I mean, I guess it’s a matter of you have to educate them into this to explain to them that the altered state can’t really be dissociated from the therapeutic state. You know, psychedelics, ketamine, all these things. It will never work on a take two and call me in the morning model.
You know, it just doesn’t work because it won’t do their work if there’s not this follow up support, both preparatory and post session.
And it seems like, I mean, I’m a strong.
I don’t have the background in neuropharmacology that you do. I have a background in psychedelics and traditional medicine. But I’m utterly convinced that these psychoneuroplastogens will not be effective in the absence of a therapeutic context. And if you have to add a therapeutic context, why not just use psychedelics? You don’t need these new compounds other than that, maybe you couldn’t patent them and so on, but why spend all of these resources to design a psychedelic that doesn’t have a therapeutic effect? It just doesn’t make any sense to me.
[00:36:15] Ranji Varghese: Yeah, yeah, no, I totally respect that and I think it may be because. And you’re absolutely right, I have.
You know, I’ll give you an example. What there’s a.
One of the reasons why people that have.
People that have very difficult to treat post traumatic stress disorder. One of the key sort of therapies that we use is called prolonged exposure therapy or exposure therapy. Well, what is exposure therapy?
Exposure therapy is essentially re. Exposing people to their trauma in a very desensitized way so that they can become more sensitized to that.
But you have people that will not go there, that cannot go there.
They’re too fearful or worried and their body is sort of frozen or stuck or in a state of fight or flight to be able to get to that state. And so this is why a lot of PTSD is very difficult to treat. One of the things that I like about ketamine, as opposed to the classical psychedelics, classical psychedelics, if depending on dose or whatever it might be, can really.
What I’ve seen is just take that fear and put it right in front of your face and that can be terrifying. Ketamine has a very special role here.
One especially through. There are different models of administering ketamine.
The most common in clinics are something called Spravata, which is a patented form of the S enantiomer of ketamine. And then the racemic mixture of ketamine given either through intramuscular or optimal IV with. In our clinic we give both.
But what we can use is with IV we can start patients off on a. Especially these difficult control patients that have PTSD, very low doses of the IV over a period of 60 minutes with support to Allow them to dip their toes into the waters of a non ordinary state and to feel comfortable as we increase the dose, infusion over infusion over infusion. So there’s some beauty in being able to sort of dial in the dosing. And even better if individuals are having a difficult time being able to help regulate them.
As you know Dennis, if you’re a sitter or facilitator, as we’re doing our clinical trials, the facilitator, the facilitators in the room, the session monitors, they’re not interpreting anything, they’re not trying to tell you to do one thing or another.
They’re there to support you.
And in that same way what we’re doing in these situations is just helping regulate individuals to allow them to be in that space. But if it is too overwhelming, I just turn the IV off. Ketamine no longer gets into their veins and it takes a little bit of time for the medicine to within 10 to 15 minutes people are right back to where they were before. And so there’s a beauty to that.
So yeah, I guess a long story of this is there’s a lot of different ways that we can use ketamine for major depressive disorder treatment, resistant depression, obsessive compulsive disorder.
There’s some data for ptsd, there’s data for patients that have substance abuse disorder, primarily alcohol, to in reductions in the amount of alcohol that they’re using.
And you know, you and I went to a conference together where we sort of, where we heard from Robin Carhart Harris and one of the things he said was, you know, why are the classical psychedelics, why is this sort of a trans diagnostic model? Why does it treat so many different types of psychiatric disorders, eating disorders, substance abuse, depression, anxiety?
And I think it, you know, we don’t really necessarily know he, we kind of think it might just be a big reset for the brain.
But it may really come down to this idea that it loosens up this rigid mind and it allows you to sort of the brain as you know, is a prediction machine, right? We are constantly trying to predict the future. Of course that’s what is, it’s really good at. If we weren’t able to predict things, we wouldn’t be able to plan things. And we’ve already planned things, we wouldn’t be able to execute on action. But if that prediction pattern is on overdrive, then it turns into rumination. If that rumination tends to be in a default way negative, then it becomes a misery and a suffering.
And if we’re able to sort of quiet down what we call priors, brain priors. We might be able to inject in new ways of thinking about the world to sort of judge with a little bit more fairness about how we see ourselves with respect to ourselves, how we see ourselves with respect to others, and more, you know, beautifully how we see each other in relation to our entire, you know, worldview. Animals, plants, just people that we don’t even know, strangers. So there’s a beauty in, in how these molecules work.
And it’s been a sort of, it’s been just a wonderful experience to, to take patients on this process. Dennis, if you can give me one minute, I just. Something came to my head and a patient. And this kind of goes to what you were saying a little bit earlier about how you’ve got to let people sort of drop into this at a.
An individual, a young lovely lady who you said, you know, the first few times I had ketamine, I just couldn’t get into it. I didn’t feel right. I just felt wasn’t there. And I just sort of said, okay, yeah, that can happen. It’s one of those things. And I said, what was it about that, that you, you know, what, what do you think that’s about? Because she said, you know, after the last few that I’ve had, it’s been different. And I said, what’s different? She goes, well, I felt like I needed to have to do something in this experience.
I was like, oh, okay, what is that about?
Well, I felt like I needed to control what was going on, like I needed to have something happen.
[00:43:01] Dennis McKenna: Right?
[00:43:01] Ranji Varghese: And I said, okay. And so what’s different now? She said, well, I just come in now. I. I know who you all are. I know I’m safe. I know what to kind of expect.
And now I just kind of go, okay, this is what my intention is for today’s session, and whatever happens, happens.
And since then, she’s able to let herself go, if you will, to be sort of, I don’t want to say vulnerable, because there’s always safety and support, we’re always checking in on patients, but an inability to sort of not control the narrative, but just to watch and observe, and you’ve taught me this through the years, is just to sort of drop in and just observe what’s up, happening. What, what is. Let’s have a sort of natural curiosity. And, you know, who does that really, really, really well.
Our children.
[00:43:55] Dennis McKenna: Yes, children. Children, exactly. Yeah. Well, children are in this super receptive state all the time. I mean, to see a child, particularly before literacy kicks in and to just see how open they are. I mean, they’re little glowing beads. It’s like these are people on acid, you know, I mean, they act like that. They are just so open, I think.
Well, you know, you mentioned Robert Carhartt Harris and his idea with the Default Mode network and the psychedelics temporarily destabilize that. And the way I like to put it, I don’t know if it’s clinically valid, but effectively it enables you to step temporarily out of your reference frame that you construct. That is another way to look at this Default Mode network that we’re in most of the time. And for some people it’s very rigid, for other people it’s a little looser. But the ability to step outside of it and not be focused so much even on yourself, to kind of step outside and realize things like the boundaries between you and nature, the boundaries between you and other people are loose. And you can make those connections, but not if you’re all bound up with this rigid imagined self protective stance. If you could let that go. I imagine that has a lot of that. What’s at the basis of that is anxiety and these things, particularly ketamine. I’ve been told that, you know, one of the first things that happens when you take ketamine is the fear goes away, effectively, the anxiety evaporates. Would you agree with that?
[00:45:54] Ranji Varghese: Yeah, yeah. You know, when I was training, I sort of had an intramuscular dose of ketamine. And one of the things I was kind of worried if this is all above board, obviously and there was a training program and I was a little concerned. I was like, well, what if I get really scared? And you know, Scott Shannon, who was the physician overseeing this, said, yeah, I mean, some people do have some fear responses. And I think I should make that point clearly here. Some people do have very sort of scary experiences under ketamine. That usually can happen when the mindset is struggling beforehand. Or is there something that’s just sort of bugging people and. Or if you go to a place where the space itself is not supportive, the people themselves are not supportive, that can antagonize that experience. But ketamine, what it does is sort of, yeah, the academy can sort of attenuate the fear response, that amygdala’s sort of hyper vigilant state and that sort of suppression of that fear response, that relaxation that occurs not only from a body response because you’re not getting this sort of tension from the body. In fact, that’s what part of that dissociation that we talked about and this is a dissociator is you’re not getting that sensory motor information and reassembling it in the ways that we normally see, assemble it in our, our cortex. And so we see this dissociation from the body and dissociation from the mind.
And that relaxation allows, hopefully allows and sort of supports the individual to sort of drop in and allow the music to sort of be a scaffold or a guide or if you will, a wave as you’re sort of riding on this surfboard on the wave. So yeah, you know Carhartt Harris’s idea about rebus r e b u s relaxed beliefs under psychedelics, that’s essentially what you’re talking about here. Ketamine does that too. It does similarly work on the default mode network.
It has this sort of immediate effect as well as sort of this neuroplastic sort of effect for a minimum of 48 hours, but really about 48 hours to maybe a week.
And while the brain is hot, while the brain is receptive, we have to strike while the iron is hot. And this is where again as you mentioned, integration sort of comes in. And let’s go back to your analogy as we were talking about children as in as much that children are baffled and curious about the world and they’re creating new, you know, synapses and learning about the world and constructing the world, the opposite can occur as well. If the curiosity of the child is, If there’s trauma that’s thrown at the child, they will fixate on that as a survival mechanism, as a survival tactic to be able to survive. And they will remember or try and construct the world in a way that they create ways of being to be
[00:49:16] Dennis McKenna: able to survive effectively. This is also what therapy can do. It’s basically teaches you how to re engineer your default mode network so that when you’re not in an altered state it works better because you’ve gone in there and you’ve made the changes while you were in this receptive neuroplastic state.
And these changes, as long as there’s the integrative therapeutic follow up, they can be long term.
One of the things I wanted to ask you about in this respect, you talk about this period of neuroplasticity after ketamine and after many psychedelics.
Ketamine is probably the shortest window for this based on what I reviewed in your notes. Ibogaine seems to be one of the longest windows And I’m wondering, what are your thoughts? So with ibogaine, apparently one remains in this neuroplastic state of receptivity for not just days, but sometimes weeks.
What difference does that make?
What does ibogaine bring to it that maybe ketamine and other psychedelics don’t? I mean, it’s definitely from people’s reports. It’s a long term process. You don’t just take ibogaine and go home. I mean, you take ibogaine and go whole, but you remain engaged in the process. There are long term effects that get sorted out over weeks, sometimes over months, sometimes over years.
Can you speak to that a bit?
[00:51:03] Ranji Varghese: I mean, one of the things that we know about classical psychedelics, if you look at questionnaires like the mystical questionnaire, the, the level of spirituality or mysticism or going beyond or ego disillusion, the higher those numbers tend to be, the greater the antidepressant effect occurs.
And if you can imagine, if you have a ketamine that you know, in a session that lasts perhaps 60 minutes with a neuroplastic window, so neurologically the plasticity of the system doesn’t last for any more than perhaps two days or so versus ibogaine, or let’s take psilocybin three weeks and say ibogaine four to six weeks or so.
Could you engage in behaviors within that four to six weeks of ongoing neuroplastic change to drive in these new neural pathways and grooves? I think the answer is perhaps that maybe one way is because you’re constantly creating.
The brain is constantly creating these new sort of network pathways.
But also with ibogaine in particular, this is a situation where people for 14, 8 to 14 hours or plus have this sort of photographic memory of their life. And they’re reliving it as if it’s on some sort of a Rolodex.
They’re just flashing over, over and over and over and over and over again. How do we sort of synthesize or metabolize that in a conceptual framework that makes us understand what that means?
Well, I’ll take a shot at it. If I were to go back and look at my life in a sort of a photographic way which would see, and it feels in that experience very realistic. And perhaps in a narrative that feels more realistic than the way my original narrative was then I get to reappraise all of that information with the knowledge
[00:53:13] Dennis McKenna: that I have now and look at a different perspective. You look at all this from a different land through a different lens. You know, and this is a point I just finished Jonathan Dickinson’s book on ibogaine and the bicameral mind. And one of the points, it’s a very interesting book, I really urge you to read it when it becomes available. But one of the things he talks about, one of the things that’s characteristic about the ibogaine experience is the encounter with this bicameral mind, which doesn’t invariably happen. But when that life review comes on and it enables you to connect with another self effectively, this is the bicameral part. It refers to Julian Jaynes model of the origin of consciousness in the bicameral mind. Effectively a second self that may reside in the right hemisphere or if it’s localized, it’s in the right hemisphere. And it’s sort of this source of.
It’s a reflection of the self. It’s like looking at yourself in the mirror but the mirror is slightly distorted. And it’s like this is a kind of a oracular wise aspect of the self that is normally closed. And when you take ibogaine you are in touch with this. And that’s where a lot of the insights and wisdom of ibogaine comes from. And it lets you, lets you not only have this life review, this kind of slideshow of your life and look at where you’ve gone off track, but it shows you paths to get out of that.
So it’s a very interesting molecule. I think it’s going to be quite important in neuroscience once some of the regulatory hurdles are passed. But what do you think about that? Not necessarily, absolutely. But the idea that it can bring sort of this second aspect of the self that is usually obscured to us forward.
And you know, we all have effectively a sage inside of us, but we’re not in touch with that sage.
[00:55:51] Ranji Varghese: I think we some are and I always sort of tell it’s how I try and explain it to us is whenever we’re going through some sort of decisions there’s some sort of intuition that might pop up. And I try and listen to that intuition and sometimes that is how I think about this sort of bottom down information that gets suppressed by the sort of the executive functioning, the prefrontal cortex that says I’m the boss here, we’ve done this for all this time, this is how we know about what the world really looks like. And you don’t have any decision making in the process here.
And I think what these psychedelics are doing is it’s allowing this sort of innate knowledge or information that would normally be suppressed by the default mode network to temporarily be appraised and then to either reject it or to say, this is correct. And then now I have to do something about it. For example, as you said, in these experiences, some. Some people might say, yes, I sort of went off the, you know, the tracks here.
And it was probably because I had, as an example, and I was probably being unfair to that person.
And what I really need to do now is I need to make amends with that person so that I can heal myself as well. And so what people do is some of the, you know, maybe the. The suffering that they’re experiencing, maybe because of the guilt and resentment or remorse that they may have had because of the relationships that may have gone cast aside. And so the healing comes from, okay, I’ve been given this sort of knowledge that maybe what I need to do is to forgive myself and for. To make amends to these individuals. And what happens, maybe these individuals, in their integration process, they reach out to the folks that they. That they may have hurt. And maybe there’s a reconnection. And then that suffering of, okay, I’m not a bad person. This person has forgiven me. But even if they’ve not forgiven me, I’m going to allow myself to be forgiven because I’ve reached out. Then maybe that suffering that they’ve experienced because of that hurt that they gave decreases just a little bit and a little bit more when they do something else, and a little bit more and a little bit more. And as you start to reduce that inner suffering and struggle, you are allowing other things to come into place that you could engage in that is more inherent to perhaps living a life that you value.
You know, Dennis, a lot of people, when they. When they’re asked on their, you know, towards the end of their life about things they may have regretted doing or not or not doing.
This is an awareness.
This is something similar. This is sort of an awareness. This is similar to how.
[00:58:55] Dennis McKenna: This is an awareness, right?
[00:58:56] Ranji Varghese: It’s. It’s an awareness they may have known all the time, oh, gosh, I shouldn’t be working this hard. I’ve got to sort of enjoy. I’ve got to stop here.
I gotta be, you know, I have to be a little bit kinder with the people around me. Sometimes people have this awareness too late in life, and it’s that awareness that sort of creates the, you know, these experiences. Psychedelics and ketamine to some degree, really catalyzes again, you know, as we would agree, was we’ve talked about set and setting in Our model at our clinic, we think about proper. There’s four S’s, there’s selection, set, setting and then support.
So when we think about selection, not everyone is a good candidate for academy, for example, or psychedelics. People that have thought disorders like schizophrenia, people that may be hypomanic or manic and can be easily switched into a manic episode, although bipolar depression is not a contraindication, strong contraindication for ketamine.
And people that may have borderline personality disorders, they may easily get dissociated in these experiences.
But the selection is very important in the process because what we don’t want to do is start someone on something or push someone into doing something without complete and utter informed consent and safety.
So selection is that process. We talked a little bit about what these individuals’ mindset going into the medicine, not only on the day of, but what’s their conceptual framework for what they think about medicine. How do they see themselves in sort of a semi vulnerable spot, even though they’re being supported by the nurses and the doctors and the care staff.
The setting, the container, of course, and then the support afterwards. So we, going back to what you were saying, it has become, we’re sort of coming full circle to psychiatry.
A lot of medicines people did psychoanalysis, you know, Freud psychoanalysis, Jung psychoanalysis. And we took the psychoanalysis and the psychotherapy out of psychiatry for a long period of time. It became sort of this very biological model and we really took that sort of spiritual and analytical component of it.
But what we’re seeing now is ketamine is sort of the gateway into reintegrating classical psychedelics into the mainstream, if you will. And so psychiatry in general needs to be aware that psychedelics will be approved. It’s just a matter of time. I’m confident, as I’m looking at and being part of these clinical trials, there are very good companies of very good people that are doing very good work in trying to get this over the gold mine.
[01:01:55] Dennis McKenna: They have ketamine as a model in a sense, because ketamine’s been available for a long time. So the opportunity has been to develop these models that can easily be transferred to the classical psychedelic psychedelics.
[01:02:11] Ranji Varghese: We have a framework. Exactly. And I’m hoping we have a framework. It’s like I’m hoping that, you know, especially all, all ketamine clinics really take that time to understand the individual sufferings, you know, identifying whether they’re supported correctly and creating that container because you’re. That only increases the chances, the probabilities that something Good can. Can come out of it. It’s, again, it’s not a, you know, a full 100% guarantee or panacea, but at least increases the chances. And this is no different than regular psychotherapy.
You know, psychotherapy with a very trusted therapist can allow people to just temporarily become less defensive, to reappraise things in their life and perhaps make changes. It doesn’t always happen in a way that we would like because there may be maybe not goodness of fit between the therapist and the patient. Maybe the individual themselves may be super defended, which is where psychedelics sort of melt those defenses away temporarily.
But psychotherapy, we’re sort of building back this scaffolding of this ceremonial, almost ritualistic way of having an arc, a story of bringing people from here to here and then re. Engaging with that. So I’m hoping that psychiatrists see this as not just a medicine to give and then saying goodbye. I think as we start to educate mental health practitioners on how to do this, we provide this sort of scaffolding and I believe the FDA will take on that approach where it isn’t just the medicine. See, you, you know, see how things go. And maybe with the psychoplastogens, maybe it will be because you don’t need all that support.
But I’d be wary about the.
[01:04:12] Dennis McKenna: Everything that we’ve discussed here makes you think psychoplastogens are not really going to work because you’ve got the substance but you don’t have the container. And I mean, this really is, I think, all about another way to view it is reintroducing spirit to medicine. And ideally you have a gifted psychotherapist who could really help a patient. But then with these tools, these tools in the hands of a gifted psychotherapist, I mean, that’s the sweet spot. That’s what you want. You want a gifted psychotherapist. And I don’t care if you call him a psychotherapy therapist or a shaman or a spiritual counselor. They understand where the patient’s coming from. They have empathy, I guess you could say. Yeah, and, and empathy is something that is often missing from the clinical situation because it doesn’t fit into the profit model. And that’s something I.
If we.
That’s something I wanted to ask you. If we develop these approaches to the effective use of these psychedelics and ketamine and ibogaine and this whole class of what you might call plastogens that facilitate this reorganization of the default mode network, that doesn’t look so good for the bottom line.
And that’s why companies are maybe reluctant because it’s hard to make a business model around that.
The take two and call me in the morning model is much better for the bottom line, but not so good for the actual therapeutic effectiveness. How is that going to be reconciled? How can you make this work in a capitalist medical therapeutic context?
[01:06:17] Ranji Varghese: Yeah, I think that it is an excellent question. I don’t have the answer for that, these very large pharmaceuticals. But I’ll tell you, I’m going to
[01:06:27] Dennis McKenna: wait for your answer. I think it is in a minute.
[01:06:30] Ranji Varghese: Well, well, I think that this is as I approach this and as my colleagues and my, my team, our team that IIT look at this, we’re just trying to push this forward so that people have the opportunity to, to, to have a different tool in, in, in the box for themselves.
And, and if you want to look at it from the, the side of, let’s say insurance companies, Insurance companies spend a lot of money on patients that will be hospitalized over and over and over and over again for maybe a suicide attempt or suicidal ideation or depression or severe ocd. And that’s hundreds and hundreds and hundreds of thousands of dollars for a two or three week stay, which is a lot of money.
But if the promise is that we give a psychedelic on day one and they come in on day 60 for their second dose and maybe on, you know, 90 days after that and all the while they’re staying out of the hospital, that may be.
[01:07:44] Dennis McKenna: The company’s gonna love that.
Absolutely.
[01:07:48] Ranji Varghese: I would hope so. I would really, really hope so. And that’s what we say. Hey, listen, if we can find something that really takes people from a state of suffering where they’re not functional at work and you’re losing productivity hours, let’s to make it very blunt, and they’re hospitalized over and over and over again, wouldn’t you want people to feel better so that they have a productive life with their friends and their families and their work that isn’t just generally good for society, but obviously good for them and also good for you, the bottom line insurance company, they may listen. And so that’s why we’re doing these studies to look at, you know, can this be done? Do we need to do this over and over again? I don’t think that’s what’s going to happen.
Now on the flip side, the pharmaceutical company is going to go, well, we’re going to have to make a profit here because if we can’t make a profit, we can’t continue to build more Molecules. And I understand that, but that’s not my field. That’s not my field. Yeah, that’s not my responsibility. I know how to.
[01:08:46] Dennis McKenna: But definitely, yes. I mean, if you can make a convincing case to the insurance companies that this is important.
But it is such a departure from the existing mindset where it’s totally medicine focused and there’s a billion, multi billion dollar industry trying to make these analogs, and it’s all about the molecule and a new molecule that hopefully we can patent and make a pile of money from. They’ve forgotten that these work within this therapeutic context. And I think that is.
That’s harder to monetize, you know, because how do you patent a protocol? I mean, I suppose you could do it, but it’s different than patenting an actual substance, you know.
[01:09:39] Ranji Varghese: Well, there are ways, Dennis. And in fact, the FDA will have a public hearing, I believe, in either August and September, and people can sort of elect to speak.
The FDA could package the delivery of some of these molecules with some sort of preparation work with a facilitator in the room and with some preparation or some integration work on the backside. In the Spravato model, which is the nasal ketamine spray, the FDA recommended that Johnson and Johnson engage in what’s called the REMS program or the Risk Evaluation Mitigation Strategy Program. And that’s just basically a framework for physicians to say, I’ve provided informed consent. I will be supportive and aware and be in the office for the entire duration of the patient’s bravado journey. I will take a blood pressure and at the beginning, in the middle, and the. At the very end, and I will make sure that there for the entire two hours. I will make sure that I have, you know, alerted the FDA to any adverse effects. So theoretically, the FDA could come back to these pharmaceutical companies and say, hey, listen, we’ll approve this. But I think we, given the fact that the majority of these studies right now that we’re involved in always have a facilitator monitor in the room just for that support, Right? And they always include some sort of a prep work and some sort of integration work to make sure that the experience is, you know, safe and supported, and the individual, the patient is sort of informed or the participant in this trial, in these trials are informed about what, you know, they’re getting into and what. What they might experience.
And so the FDA may come back and say, sure, will allow you to do this, but you’re going to have to have a facilitator for, you know, the first two or three times. And you have to have some preparation work and some integration work. Preparation. And, and so that is really then going to be. And if that comes to fruition, then that’s going to be a problem of scaling because how many psychiatric offices are going to have the rooms available for a six to eight hour journey and have to hire a facilitator to do prep work, integration work, facilitation? That’s something to be seen and we’ll see how it pans out. At the end of the day, I mean, I think people who will want to sort of venture into psychedelics will find it, you know, on their own in the underground spaces.
And my hope is, if they do do that, that they are completely in a safe space, not only with the facilitator, but what, whatever medicine that they’re experiencing on making sure in my, in our clinic we actually provide consultations for harm reduction, you know, services, so that if someone says, hey, I’m going to Costa Rica, I’m gonna have an ayahuasca experience. I’m on these medications, is this safe for me? We provide them with that information. We tell them, here’s what you should, probably should not stay on and so forth, and let them know what could come up for them and what the benefits and the potential risks are based on the data.
[01:13:03] Dennis McKenna: And that may be where the opportunity is to provide basically to educate people that might seek out these kinds of experiences. I think maybe the solution is there’s a great deal of community wisdom out there. If you look at these traditional practices, and I go on, I talk about symbiosis a lot. I mean, people can go directly to nature.
They don’t really have to ask the FDA for permission to go find mushrooms and take mushrooms, I think, or whatever the plant is. Mushrooms are an example of one of the ones that are freely available. People can find these things in nature, they can take them. That doesn’t mean they’re safe necessarily without a context, but they can look at the sort of traditional practices.
And now there have been sophisticated, there’s a community wisdom that’s built up over the years since psychedelics have been part of our culture, at least since the early 70s. So there are a lot of people, they may not be credentialed, but they know how to use them. They know how to use them. And they either have done apprenticeships with curaderos or they’ve undergone. Well, as you know, ciis and other organizations have courses in psychedelic therapy.
[01:14:39] Ranji Varghese: Absolutely.
[01:14:40] Dennis McKenna: Very related to the clinical approach.
But people can find these therapeutic opportunities within a supportive community.
I’ve often gone on about how communities can establish wellness centers effectively in which people could go to for a spectrum of treatments and that might include psychedelics on the menu with the guidance of a well trained facilitator is the neutral term. But perhaps somebody that is trained in these positions, in these processes. Of course, one of the.
What of the pitfalls, One of the challenges, and I think this is true in any situation.
Not just psychedelic practices, but spiritual practices in general.
There’s a vulnerability to people who perhaps have, I don’t know what you’d call it, loose ethics. But people who view these kinds of things as opportunities to.
For power, they find themselves into every situation. There are plenty of examples of psychiatrists abusing their patients. The whole Vancouver MDMA protocol, a spectacular example. How do you deal with people that present themselves as compassionate facilitators that are actually sociopaths?
[01:16:27] Ranji Varghese: Yeah, yeah, this is the danger, Dennis, and this is my worry.
So I, I think that anyone. Let’s, let’s, let’s take two different examples. Let’s say psychedelics become approved. I’m hoping that whoever is able to sort of provide these sort of medicines have a, some sort of a training course. There are different types of courses for facilitating prepping integration. Our clinic at iit, we have a ketamine assisted program.
Another one is fluence. You mentioned CIIs. I did my training through Pradi in Colorado.
And you know, in every one of these experiences, whenever we hire individuals to prepare for, you know, facilitating ketamine, we do a background check with them, we check their references and we make sure that we’re monitoring them as they are proceeding. But that’s just our clinic and we have high ethical standards and expectations. I’m hoping that if this model of molecules become sort of available through the fda, that there’s some level of, you know, scrutiny that happens. Because as you said, during these states, people are very vulnerable.
And this is when I was on the governor’s task force and created this task report. My, my. I was the one of the only physicians on this task force and my sole priority was how do we make this safe for people? How if we legalize psychedelics in the state of Minnesota and if there’s sort of a state sponsored program that there are sort of guardrails, that whoever, you know, applies to become a facilitator has to go through some sort of a program and is vetted and is to continuously be sort of monitored for that and that’s what we wrote into the legislation. Legislation.
[01:18:26] Dennis McKenna: It’s, it’s sort of obvious. I mean, there, there does need to be some level of regulation and qualification of these facilitators. You would ask, you would expect any physician that you might go to for whatever, you would expect your oncologist to have the training to treat cancer.
And a person does not have to be a physician to be a good facilitator, but they do need that education, probably with the help of physicians. So it’s, it’s, it’s a perpetual problem, but it, in some ways, it’s the human nature problem. You know, in a certain way, not everybody is a saint and there are really bad people out there, you know. Right.
[01:19:17] Ranji Varghese: And as you said, as you said, this is life, this is human nature. Sometimes people will be drawn into these sort of positions because they will be in a position of power, which is where this informed consent also comes about.
[01:19:34] Dennis McKenna: Right.
[01:19:35] Ranji Varghese: In our clinic, everyone is sort of monitoring one another. The informed consent about what is available as touch. Touch is only available as putting a hand on a shoulder or holding a hand for a period of time. That informed consent happens always before the session and never during because people cannot be trusted to be able to make, you know, an informed decision during that session. We’re never going to be able to control any of that, but we can put some sort of pieces in place to support the person that is at their most vulnerable state. And that’s the number one priority. And I hope that we can get there. And I will. I believe that we can get there. And I hope that, you know, we, we push for that as, as, as the number one priority. We know these things can work. We need to prioritize patient safety. And as you said, Dennis, you don’t have to be a brilliant sort of Maryland, PhD master’s level social worker. A facilitator can be very good at what they do.
But one of the key ingredients that you described earlier was empathy, which really, really is about love, loving, and not in any sort of weird way, but just caring about the individual, caring about that person as they. Empathy and the openness and also the preparation of that facilitator to be able to hold space if something doesn’t go right. And that’s where I think, you know, you, you, you can have these training programs fly by night training programs, but that doesn’t necessarily equip you if something goes in a way that, you know, if, if that can trigger something within that. The facilitator.
[01:21:26] Dennis McKenna: Yeah.
[01:21:27] Ranji Varghese: So it’s important for facilitators to also be aware of their own blind spots, of their own things that might be able to. That might trigger them. Well, it’s pretty complicated.
[01:21:40] Dennis McKenna: Yeah, life is complicated, Ranji. People are complicated, so of course it is. No, they should. Well, you know, as you mentioned in your program notes, I mean, ayahuascaros, typically, they might trade for decades, you know, it for them, it is an ongoing process. It’s not like you take a course and you’re set, you know, because it’s an ongoing, lifelong learning process. Not only for the people that might come for these experiences, but the people who are lifelong curaderos or whatever, facilitators of some kind. It’s an ongoing learning process.
If you reach a point where you think, well, I know everything I need to know and I’m ready to hang out my shingle and treat other people, that’s a good point to back up and say, am I really ready to do this? Am I really qualified to do this? You know, a serious talk with yourself about why am I doing this and what are the constraints as well as the opportunities. So, Renji, we’ve gone more than an hour and a half. We barely touched, We’ve barely scratched the surface here, but maybe we’ve got some. We could always revisit this. Is there anything that we haven’t discussed? Well, I mean, there’s tons of stuff.
I’ve got your notes in front of me. We could go on and on and on, but maybe it’s a good time to end it. But is there anything that we haven’t said yet, that you really want to be sure? We do say
[01:23:32] Ranji Varghese: First, I just want to end by saying the molecule is not the medicine.
The experience is the medicine. That’s the molecule is how you get there.
[01:23:42] Dennis McKenna: That’s.
Yep.
[01:23:45] Ranji Varghese: And secondly, a big thank you to you, Dennis, for being a mentor to me, a friend to me, for creating this platform to exponentially reach people that may not know much about ketamine or psychedelics and to make and hopefully educate them to say that this is.
This is real and it’s okay. And, and, and really, people that are very ethical, that are hard working, are doing their best to try and get help to people that need it. So thank you.
[01:24:27] Dennis McKenna: Yes. Well, thank you, Ranji, for. You’re a pioneer with this and you’re one of the ones basically implementing this changing paradigm. And it does need to change. We all know that mental health care is in crisis and there are better approaches. So it’s emerging. And you’re on the edge of that. And from what I know of you personally, I’m confident that, you know, we need more people like you, Ranji, join this work.
And I’m just so honored to be able to call you my friend. You’ve been a mentor to me, too.
And, you know, you’ve saved my life. As you know, your treatment that you gave me for my sleep, that’s how we got to know each other.
But now here we are, we’re friends, and we’re exploring these very important sort of edges of frontiers, if you will, of consciousness and what it is to be a human being.
And being a human being, a curious monkey, is calm. You know, it’s challenging. It’s not an easy thing, you know, but you’ve done a lot to educate people about these things and help people become better human beings. And that’s the point, right? As Rick Doblin once said. Rick Doblin says lots of things, but one thing he said that really has stuck with me. He said people don’t take psychedelics to have psychedelic experiences. They take psychedelics to have better human experiences.
And I think that’s absolutely true.
So you’ve helped advance that, and I really appreciate you, and I appreciate your affiliation with the McKenna Academy. That’s a feather in our cap, for sure.
And so far, we haven’t embarrassed you, I hope, and there’s still plenty of time for that. But we’re trying to do the right thing.
And so it’s been an absolute pleasure to have this conversation with you.
[01:26:52] Ranji Varghese: Absolutely. Dennis, thank you so much. You take care.
[01:26:54] Dennis McKenna: Thank you, Ranji. We’ll be in touch.